Today the National Grange supported the release of a new analysis by Magnolia Market Access examining how Medicare hospital reclassification policies are increasingly diverting resources intended for ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful. The 340B program ...

The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...

The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

The 340B Drug Discount Program was designed to help safety-net providers make drugs available to low-income patients and earn revenue. Drug manufacturers have put restrictions on which pharmacies ...

Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "MFN reinforces the worst incentives in 340B, shifts costs ...

Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Contract pharmacies began as a pragmatic response to assist low-resourced clinics and hospitals that did not have an in-house pharmacy. Many of the program’s earliest participants—Federally Qualified ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...